Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Brief Title: Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

11 de noviembre de 2026 actualizado por: Zeenat Usman, Shaheed Zulfiqar Ali Bhutto Medical University

EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL

Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Zeenat Usman, MS obstetrics and Gyanecology
  • Número de teléfono: +923315333910
  • Correo electrónico: usmanbut2@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Quratulain Assosciate Professor, FCPS - Obstetrics and Gynaecol
  • Número de teléfono: +92335587882
  • Correo electrónico: qurratulain_saeed@yahoo.com

Ubicaciones de estudio

    • Islamabad
      • Islamabad, Islamabad, Pakistán, 04485
        • Pakistan Institute of Medical Sciences (PIMS)
        • Contacto:
        • Contacto:
          • Quratulain Associate Professor, FCPS - Obstetrics and Gynaecol
          • Número de teléfono: +92335587882
          • Correo electrónico: qurratulain_saeed@yahoo.com
        • Investigador principal:
          • Zeenat Usman, MS obstetrics and gyane
        • Sub-Investigador:
          • Quratulain Saeed, FCPS - Obstetrics and Gynaecol
        • Sub-Investigador:
          • Tooba Batool

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Women aged 18 years or older.
  • Women scheduled to undergo an eligible transcervical uterine procedure under total intravenous anaesthesia (TIVA).
  • Women with stable haemodynamic condition before surgery.

Exclusion Criteria:

  • Known allergy or hypersensitivity to lidocaine or other planned local anaesthetic.
  • Significant hepatic disease affecting local anaesthetic metabolism.
  • Chronic opioid use or chronic pain requiring regular analgesic therapy.
  • Major intraoperative complication requiring deviation from the standardized anaesthetic or surgical protocol.
  • Patients requiring emergency surgery where informed consent or standardized study procedures cannot safely be completed.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Paracervical Block Plus Standard Analgesia

Participants will receive a standardized paracervical block using lidocaine in addition to standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures. Postoperative pain scores and analgesic requirements will be assessed and compared with the control group.

A standardized paracervical block will be administered after induction of total intravenous anesthesia (TIVA) and before uterine manipulation. The technique will use 2% lidocaine without adrenaline, with 1 mL injected at each of four cervical positions (2, 4, 8, and 10 o'clock), for a total volume of 4 mL (80 mg lidocaine). Aspiration will be performed before and during injection to reduce the risk of intravascular administration. The block will be given in addition to standard TIVA and perioperative analgesia for eligible transcervical uterine procedures.

Sin intervención: Standard Analgesia Alone

Participants will receive standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures without a paracervical block. Postoperative pain scores and analgesic requirements will be assessed and compared with the intervention group.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative Pain Score (0-10 Visual Analogue Scale [VAS] Score)
Periodo de tiempo: From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.

Postoperative pain intensity will be measured using a 0-10 Visual Analogue Scale (VAS), with 0 representing no pain and 10 representing the worst imaginable pain. The VAS score will be recorded for each participant at recovery room arrival (when awake and able to communicate), 30 minutes, 1 hour, 2 hours, and 4 hours after the procedure, where feasible. The mean or median postoperative pain scores will be compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Participants Requiring Rescue Analgesia (%)
Periodo de tiempo: From completion of the procedure until 4 hours post-procedure.

The proportion of participants requiring additional rescue analgesia for postoperative pain despite receiving standard perioperative analgesia will be recorded. Rescue analgesia requirement will be assessed as a binary outcome (Yes/No) using the study Case Report Form (CRF). The percentage of participants requiring rescue analgesia will be compared between the intervention and control groups.Control group is the one receiving standard analgesia that is only TIVA and case group is standard analgesia that is TIVA and paracervical block group

From completion of the procedure until 4 hours post-procedure.
Time to First Rescue Analgesia (Minutes)
Periodo de tiempo: From completion of the procedure until 4 hours post-procedure

Time to first rescue analgesia will be measured in minutes from completion of the transcervical uterine procedure to administration of the first rescue analgesic. The time of administration will be documented using the medication administration record and structured Case Report Form (CRF), and compared between the two study groups.

From completion of the procedure until 4 hours post-procedure
Total Postoperative Rescue Analgesic Requirement (Drug-Specific Dose)
Periodo de tiempo: From completion of the procedure until 4 hours post-procedure.

The total dose of additional rescue analgesic medication administered to each participant for postoperative pain will be recorded using the medication administration record and structured Case Report Form (CRF). The drug name, individual dose and total dose administered during the postoperative observation period will be documented and compared between the two study groups. Results will be expressed in the appropriate drug-specific dose units (e.g., milligrams).

From completion of the procedure until 4 hours post-procedure.
Patient Satisfaction Score with Postoperative Pain Management (5-Point Likert Scale)
Periodo de tiempo: At the end of the postoperative recovery observation period, up to 4 hours after the procedure.

Participant satisfaction with postoperative pain management will be assessed using a predefined 5-point Likert scale recorded on the structured Case Report Form (CRF). The scale ranges from 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), to 5 (very satisfied). Individual satisfaction scores will be recorded and compared between the two study groups.

At the end of the postoperative recovery observation period, up to 4 hours after the procedure.
Time to First Mobilization (Minutes)
Periodo de tiempo: From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.

Time to first mobilization will be measured in minutes from completion of the transcervical uterine procedure to the participant's first mobilization. The time will be recorded using the structured Case Report Form (CRF) and compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.
Incidence of Postoperative Nausea and Vomiting (Number and Percentage of Participants)
Periodo de tiempo: From arrival in the recovery area until 4 hours after completion of the procedure.

The incidence of postoperative nausea and vomiting will be assessed by recording the presence or absence of nausea and vomiting (Yes/No) using the structured Case Report Form (CRF). The requirement for rescue antiemetic medication will also be documented as Yes or No. Results will be expressed as the number and percentage of participants experiencing nausea and vomiting in each study group.

From arrival in the recovery area until 4 hours after completion of the procedure.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Zeenat Usman, MS obstetrics and Gyanecology, SZABMU,PIMS

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

30 de abril de 2027

Finalización del estudio (Estimado)

30 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

24 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • F-5-2/2024(ERRC)30th-PIMS

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data collected during this study will not be shared publicly or made available to external researchers. Data will be used by the study investigators for the purposes of the approved research. Participant confidentiality will be maintained in accordance with institutional ethical requirements.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .